Evidence map›Paper›PMID 40177645›Full record

ReviewAntibody therapeutics2025

A systematic review of the avian antibody (IgY) therapeutic effects on human bacterial infections over the decade.

Zahra Esmaeili, Sara Kamal Shahsavar, Kiarash Ghazvini

Abstract readReview
In one paragraph

Review in Antibody therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Efficacy of IgY onAntibody therapeutics · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zahra EsmaeiliDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177949025, Iran.ORCID https://orcid.org/0000-0002-6098-7471
Sara Kamal ShahsavarDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177949025, Iran.
Kiarash GhazviniDepartment of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad 9177949025, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The overuse of antibiotics worldwide, especially during the Coronavirus pandemic, has raised concerns about the rise of antibiotic resistance and its side effects. Immunoglobulin Y, a natural protein that specifically targets foreign antigens, holds promise as a potential therapeutic option, particularly for individuals with sensitive immune systems. Despite numerous studies on IgY, the optimal administration method, effective dose, target antigen, and potential side effects of this antibody remain areas of active research and challenge. This review selected and evaluated articles published in the last ten years from databases such as PubMed and Science Direct with appropriate keywords discussing the therapeutic effects of immunoglobulin Y in human infections

Indexed as

adverse reactionsIgYimmunoproteinsinfection controlpassive immunitytherapeutic effects

Identifiers

PMID40177645
PMCPMC11959693

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.